1
|
Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget 2017; 7:22543-55. [PMID: 26968814 PMCID: PMC5008380 DOI: 10.18632/oncotarget.8002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 02/24/2016] [Indexed: 12/21/2022] Open
Abstract
Somatic mutation analysis represents a useful tool in selecting personalized therapy. The aim of our study was to determine the presence of common genetic events affecting actionable oncogenes using a MassARRAY technology in patients with advanced solid tumors who were potential candidates for target-based therapies. The analysis of 238 mutations across 19 oncogenes was performed in 197 formalin-fixed paraffin-embedded samples of different tumors using the OncoCarta Panel v1.0 (Sequenom Hamburg, Germany). Of the 197 specimens, 97 (49.2%) presented at least one mutation. Forty-nine different oncogenic mutations in 16 genes were detected. Mutations in KRAS and PIK3CA were detected in 40/97 (41.2%) and 30/97 (30.9%) patients respectively. Thirty-one patients (32.0%) had mutations in two genes, 20 of them (64.5%) initially diagnosed with colorectal cancer. The co-occurrence of mutation involved mainly KRAS, PIK3CA, KIT and RET. Mutation profiles were validated using a customized panel and the Junior Next-Generation Sequencing technology (GS-Junior 454, Roche). Twenty-eight patients participated in early clinical trials or received specific treatments according to the molecular characterization (28.0%). MassARRAY technology is a rapid and effective method for identifying key cancer-driving mutations across a large number of samples, which allows for a more appropriate selection for personalized therapies.
Collapse
Affiliation(s)
- Maider Ibarrola-Villava
- Hematology and Medical Oncology Unit, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Tania Fleitas
- Hematology and Medical Oncology Unit, Biomedical Research Institute INCLIVA, Valencia, Spain
| | | | - Cristina Mongort
- Department of Pathology, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Elisa Alonso
- Department of Pathology, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Samuel Navarro
- Department of Pathology, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Octavio Burgues
- Department of Pathology, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Ana Vivancos
- Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Juan Miguel Cejalvo
- Hematology and Medical Oncology Unit, Biomedical Research Institute INCLIVA, Valencia, Spain
| | | | - Susana Roselló
- Hematology and Medical Oncology Unit, Clinic University Hospital of Valencia, Valencia, Spain
| | - Gloria Ribas
- Hematology and Medical Oncology Unit, Biomedical Research Institute INCLIVA, Valencia, Spain
| | - Andrés Cervantes
- Hematology and Medical Oncology Unit, Biomedical Research Institute INCLIVA, Valencia, Spain.,Department of Medicine, University of Valencia, Valencia, Spain
| |
Collapse
|
2
|
Thumar J, Giesen E, Kluger HM. Drug targets and predictive biomarkers in the management of metastatic melanoma. PHARMACOGENOMICS & PERSONALIZED MEDICINE 2012; 5:139-48. [PMID: 23226069 PMCID: PMC3513235 DOI: 10.2147/pgpm.s25100] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Indexed: 12/05/2022]
Abstract
Melanoma is the leading cause of fatal skin cancer, and in the past few decades, there has been an increase in the incidence of and mortality from metastatic melanoma. Until recently, the therapeutic options for treatment of metastatic melanoma were limited. The approval of ipilimumab (an anti-CTLA-4 antibody) and vemurafenib (mutant B-RAFV600E kinase inhibitor) by the Federal Drug Administration has led to a new era in melanoma treatment, and additional promising drugs and drug combinations are currently being investigated. As the choices of treatment for melanoma have expanded, the need to identify predictive biomarkers to tailor treatment strategies to individual tumor or immune system characteristics has become necessary. Such strategies have the potential of maximizing antitumor effect while minimizing toxicity and improving clinical benefit. In this article, we review the currently approved targeted therapies in melanoma and discuss the future of personalized therapy for this disease.
Collapse
Affiliation(s)
- Jaykumar Thumar
- Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
| | | | | |
Collapse
|
3
|
Schoenewolf NL, Bull C, Belloni B, Holzmann D, Tonolla S, Lang R, Mihic-Probst D, Andres C, Dummer R. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012; 48:1842-52. [DOI: 10.1016/j.ejca.2012.02.049] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2011] [Revised: 02/07/2012] [Accepted: 02/15/2012] [Indexed: 11/25/2022]
|
4
|
Dutton-Regester K, Irwin D, Hunt P, Aoude LG, Tembe V, Pupo GM, Lanagan C, Carter CD, O'Connor L, O'Rourke M, Scolyer RA, Mann GJ, Schmidt CW, Herington A, Hayward NK. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol Cancer Ther 2012; 11:888-97. [PMID: 22383533 DOI: 10.1158/1535-7163.mct-11-0676] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Success with molecular-based targeted drugs in the treatment of cancer has ignited extensive research efforts within the field of personalized therapeutics. However, successful application of such therapies is dependent on the presence or absence of mutations within the patient's tumor that can confer clinical efficacy or drug resistance. Building on these findings, we developed a high-throughput mutation panel for the identification of frequently occurring and clinically relevant mutations in melanoma. An extensive literature search and interrogation of the Catalogue of Somatic Mutations in Cancer database identified more than 1,000 melanoma mutations. Applying a filtering strategy to focus on mutations amenable to the development of targeted drugs, we initially screened 120 known mutations in 271 samples using the Sequenom MassARRAY system. A total of 252 mutations were detected in 17 genes, the highest frequency occurred in BRAF (n = 154, 57%), NRAS (n = 55, 20%), CDK4 (n = 8, 3%), PTK2B (n = 7, 2.5%), and ERBB4 (n = 5, 2%). Based on this initial discovery screen, a total of 46 assays interrogating 39 mutations in 20 genes were designed to develop a melanoma-specific panel. These assays were distributed in multiplexes over 8 wells using strict assay design parameters optimized for sensitive mutation detection. The final melanoma-specific mutation panel is a cost effective, sensitive, high-throughput approach for identifying mutations of clinical relevance to molecular-based therapeutics for the treatment of melanoma. When used in a clinical research setting, the panel may rapidly and accurately identify potentially effective treatment strategies using novel or existing molecularly targeted drugs.
Collapse
Affiliation(s)
- Ken Dutton-Regester
- Queensland Institute of Medical Research, Oncogenomics Laboratory, Queensland University of Technology, Brisbane, Queensland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Dutton-Regester K, Hayward NK. Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2012; 65:399-435. [PMID: 22959033 DOI: 10.1016/b978-0-12-397927-8.00013-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Melanoma has historically been refractive to traditional therapeutic approaches. As such, the development of novel drug strategies has been needed to improve rates of overall survival in patients with melanoma, particularly those with late stage or disseminated disease. Recent success with molecularly based targeted drugs, such as Vemurafenib in BRAF-mutant melanomas, has now made "personalized medicine" a reality within some oncology clinics. In this sense, tailored drugs can be administered to patients according to their tumor "mutation profiles." The success of these drug strategies, in part, can be attributed to the identification of the genetic mechanisms responsible for the development and progression of metastatic melanoma. Recently, the advances in sequencing technology have allowed for comprehensive mutation analysis of tumors and have led to the identification of a number of genes involved in the etiology of metastatic melanoma. As the methodology and costs associated with next-generation sequencing continue to improve, this technology will be rapidly adopted into routine clinical oncology practices and will significantly impact on personalized therapy. This review summarizes current and emerging molecular targets in metastatic melanoma, discusses the potential application of next-generation sequencing within the paradigm of personalized medicine, and describes the current limitations for the adoption of this technology within the clinic.
Collapse
Affiliation(s)
- Ken Dutton-Regester
- Queensland Institute of Medical Research, Oncogenomics Laboratory, Brisbane QLD 4006, Australia
| | | |
Collapse
|
6
|
Schoenewolf NL, Urosevic-Maiwald M, Dummer R. Tumour heterogeneity of mucosal melanomas during treatment with imatinib. Br J Dermatol 2011; 165:419-24. [PMID: 21495997 DOI: 10.1111/j.1365-2133.2011.10376.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A comparison of in vitro and in vivo characteristics of tumour cells derived from patients with mucosal melanoma treated with imatinib was performed with respect to KIT mutations. Three patients with mucosal melanoma were treated with imatinib. Patient-derived tumour material was used to establish melanoma cell cultures ex vivo. We evaluated tumour material and cell cultures for KIT protein expression and KIT mutation status. In addition, proliferation assays with melanoma cell cultures were performed with imatinib. Expression of KIT protein and KIT mutation was shown in two patients who responded to imatinib in vivo. Cells derived from a third patient who did not respond to imatinib did not express KIT and lacked a KIT mutation. Patient-derived melanoma cells did not show any KIT mutations, nor did they respond to imatinib in vitro. Our study underlines that melanoma consists of a heterogeneous cell population, making it imperative to use the mapping of involved activating tumour growth-driving pathways in order to improve response to therapy with kinase inhibitors.
Collapse
Affiliation(s)
- N L Schoenewolf
- Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
| | | | | |
Collapse
|